Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Privia Health (PRVA) Tax Provisions (2020 - 2025)

Historic Tax Provisions for Privia Health (PRVA) over the last 6 years, with Q3 2025 value amounting to $6.9 million.

  • Privia Health's Tax Provisions rose 7250.0% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year increase of 3899.66%. This contributed to the annual value of $10.8 million for FY2024, which is 3544.35% up from last year.
  • As of Q3 2025, Privia Health's Tax Provisions stood at $6.9 million, which was up 7250.0% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Privia Health's Tax Provisions registered a high of $6.9 million during Q3 2025, and its lowest value of -$20.0 million during Q2 2021.
  • For the 5-year period, Privia Health's Tax Provisions averaged around -$209789.5, with its median value being $2.1 million (2025).
  • Its Tax Provisions has fluctuated over the past 5 years, first crashed by 1854146.34% in 2021, then surged by 21540.0% in 2022.
  • Over the past 5 years, Privia Health's Tax Provisions (Quarter) stood at -$7.6 million in 2021, then crashed by 75.94% to -$13.4 million in 2022, then skyrocketed by 114.46% to $1.9 million in 2023, then skyrocketed by 35.08% to $2.6 million in 2024, then skyrocketed by 162.76% to $6.9 million in 2025.
  • Its last three reported values are $6.9 million in Q3 2025, $2.5 million for Q2 2025, and $2.1 million during Q1 2025.